Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release endogenous growth hormone. Its primary healthspan relevance is its proven, potent ability to selectively reduce visceral adipose tissue (VAT), a key driver of age-related metabolic dysfunction and systemic inflammation. It may also offer secondary benefits for cognitive function in older adults by increasing levels of GABA and other neurochemicals.
Verdict
A powerful, targeted tool for visceral fat reduction under medical supervision.
HEALTHSPAN IMPACT
High Value
RISK LEVEL
High
EVIDENCE GRADE
A
MONTHLY COST
$2000 - $5000
Protocol
- 1 mg daily via subcutaneous injection, often cycled 5 days on, 2 days off.
Flags
- Requires a prescription and ongoing medical supervision.
- May increase IGF-1 levels, with unknown long-term effects on cancer risk.
- Can negatively impact insulin sensitivity and blood glucose control.
- Contraindicated in individuals with active malignancy.
- Common side effects include joint pain (arthralgia) and fluid retention.